Testosterone treatment improves liver function and reduces cardiovascular risk: A long-term prospective study

Figures & data

Figure 1. Flow-chart of patient’s recruitment (T-group and C-group)

Table 1. Baseline characteristics of the T-group and C-group

Characteristic	T-group	C-group	P
N	312	184
Mean (SD):
Age, years	59 (9.5)	66.1 (7.6)
Testosterone level, nmol/L	7.81 (2.32)	9.22 (3.41)	<0.001
WC, cm	107.51 (9.95)	100.76 (9.54)	<0.001
Weight, kg	98 (12)	92 (9)	NS
BMI, kg/m^2	31.54 (4.51)	29.50 (3.31)	<0.001
FLI	83.70 (12.15)	68.81 (19.27)	<0.001

NS, not statistically significant.

Figure 2. The TT levels at baseline and over the 8-year period for the 312 hypogonadal men in the T-group and 184 untreated hypogonadal men in the C-group (*P < 0.001)

Figure 3. The FLI at baseline and over the 8-year period for the 312 hypogonadal men in the T-group and 184 untreated hypogonadal men in the C-group. *significant; N.S., not significant

Figure 4. The γ-GT levels at baseline and over the 8-year period for the 312 hypogonadal men in the T-group and 184 untreated hypogonadal men in the C-group (*P < 0.001). N.S., not significant

Figure 5. The bilirubin levels at baseline and over the 8-year period for the 312 hypogonadal men in the T-group and 184 untreated hypogonadal men in the C-group. N.S., not significant

Figure 6. The AST levels at baseline and over the 8-year period for the 312 hypogonadal men in the T-group and 184 untreated hypogonadal men in the C-group (*P < 0.001). N.S., not significant

Figure 7. The ALT levels at baseline and over the 8-year period for the 312 hypogonadal men in the T-group and 184 untreated hypogonadal men in the C-group. N.S., not significant

Figure 8. The triglyceride levels at baseline and over the 8-year period for the 312 hypogonadal men in the T-group and 184 untreated hypogonadal men in the C-group (*P < 0.001)

Figure 9. The BMI (kg/m²) at baseline and over the 8-year period for the 312 hypogonadal men in the T-group and 184 untreated hypogonadal men in the C-group (*P < 0.001)

Figure 10. The WC at baseline and over the 8-year period for the 312 hypogonadal men in the T-group and 184 untreated hypogonadal men in the C-group (*P < 0.001)

Table 2. Comparison of adverse events between the T-group following long-term treatment with TU and the C-group

Adverse events	T-group	C-group	P
N	312	184
Deaths, n (%)	25 (7.8)	28 (15.2)	0.035
Deaths due to CVD, n (%) Myocardial infarction Stroke Heart failure Aortic aneurysm Lung embolism	11 (44)* 5 (20) 2 (8) 2 (8) 1 (4) 1 (4)	28 (100) 13 (48) 7 (27) 3 (11) 2 (7) 2 (7)

*P < 0.001.